What Happened

A pharmacist who co-owned and served as pharmacist-in-charge of Healthcare Pharmacy in Trenton, New Jersey was convicted by a federal jury of conspiring to unlawfully distribute Schedule II controlled substances and maintaining a drug-involved premises.

Between 2014 and 2017, she and employees acting at her direction filled fraudulent prescriptions outside the usual course of professional practice, knowing the drugs would not be used for a legitimate medical purpose. Operating a single-location pharmacy, she purchased and distributed millions of dosage units of oxycodone — over 800,000 pills in 2014, over 900,000 in 2015, over 800,000 in 2016, and over 200,000 in 2017, the year the DEA suspended the pharmacy's registration — much of it diverted to street-level drug dealers. She evaded state and federal reporting requirements by manipulating the pharmacy's records. A DEA audit found more than 64,000 oxycodone pills diverted between April 2015 and August 2017 alone.

Following a two-week trial, a federal jury convicted her on two counts: conspiracy to unlawfully distribute and dispense Schedule II controlled substances, and maintaining a premises for the illegal distribution of controlled substances. A third distribution count was dismissed before trial. The conspiracy charge carries a maximum of 20 years in prison and a $1 million fine; the drug-involved-premises charge carries a maximum of 20 years and a $500,000 fine. Sentencing was pending as of the announcement.

What Went Wrong

A pharmacy owner used sole control over a single-location pharmacy to fill millions of fraudulent prescriptions for years before being stopped. Key failure points:

  • Owner-level control eliminated internal checks. As co-owner and pharmacist-in-charge, she directed employees to fill prescriptions outside the usual course of practice, with no independent pharmacist positioned to question her authority.
  • Purchasing volume was not flagged for years. Distributing over 800,000 oxycodone pills in a single year at one small retail location is a volume far outside normal dispensing patterns, yet the pharmacy continued operating at that scale for at least four years before DEA suspended its registration.
  • Falsified records concealed the gap between purchases and legitimate dispensing. Manipulating pharmacy records to evade state and federal reporting requirements meant regulators lacked accurate data to detect the diversion sooner.
  • Diverted product reached street-level distribution. The fraudulent prescriptions were not confined to personal use; oxycodone reached street-level drug dealers, indicating the scheme functioned as a wholesale diversion channel rather than isolated misconduct.

How It Could Have Been Prevented

  • Flag pharmacies whose controlled-substance purchase volumes are statistical outliers relative to their size and patient population, and require justification for sustained high-volume ordering.
  • Require distributor-level suspicious order monitoring under the Controlled Substances Act to catch a single-location pharmacy ordering hundreds of thousands of oxycodone units annually.
  • Conduct independent, unannounced state board or DEA inventory audits rather than relying on pharmacy-submitted records alone.
  • Cross-reference dispensing records against the state prescription drug monitoring program (PDMP) to identify prescriptions inconsistent with prescriber patterns.
  • Require a second pharmacist's sign-off on prescriptions filled by an owner or pharmacist-in-charge to prevent unilateral control over both authorization and dispensing.

Related Guidance

Sources